Filing Flows

Filing Flows › Companies › Roivant Sciences › Cash flow

Roivant Sciences cash flow, quarter by quarter

Latest: Q1 FY27 · from the cash-flow statements filed with the SEC

Free cash flow−$271M in Q1 FY27 · −$821M over twelve months

Operating cash flow−$271M
Capital spending−$419K
Free cash flow−$271M

Analysis

In Q1 FY27, Roivant Sciences generated −$271M of operating cash flow and spent $419K on capital projects, leaving free cash flow of −$271M. That is $62.5M less than in Q1 FY26 (−$208M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$816M; the largest uses were operating cash flow ($816M), other financing ($174M), capital spending ($4.6M); besides operations, cash came from other investing ($689M), shares issued ($314M); the cash balance rose by $11.9M.

Operating cash flow was −$271M against net income of −$291M. The largest differences: stock-based pay +$83.3M, gains on investments −$36.6M, prepaid and other assets −$23.8M.

Free cash flow

Roivant Sciences: free cash flow by quarterRoivant Sciences: free cash flow by quarter−$268MQ2 FY25−$209MQ3 FY25−$173MQ4 FY25−$208MQ1 FY26−$194MQ2 FY26−$192MQ3 FY26−$165MQ4 FY26−$271MQ1 FY27
Operating cash flow less capital spending.
Roivant Sciences: operating cash flow against capital spendingRoivant Sciences: operating cash flow against capital spendingOperating cash flowCapital spending−$267M$996KQ2 FY25−$207M$1.8MQ3 FY25−$173M$811KQ4 FY25−$204M$4.0MQ1 FY26−$186M$7.8MQ2 FY26−$196M−$4.9MQ3 FY26−$164M$1.3MQ4 FY26−$271M$419KQ1 FY27
Latest (Q1 FY27): Operating cash flow −$271M, Capital spending $419K.

Capital allocation, year by year

Roivant Sciences: where the cash came from (up) and went (down), by fiscal yearRoivant Sciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingBuybacksFY22: Operating cash flow −$678MFY22: Shares issued $412KFY22: Capital spending −$17.4M$412KFY22FY23: Operating cash flow −$843MFY23: Net borrowing −$692KFY23: Shares issued $315MFY23: Capital spending −$12.7M$315MFY23FY24: Operating cash flow −$765MFY24: Net borrowing −$1.5MFY24: Shares issued $254MFY24: Capital spending −$1.4M$254MFY24FY25: Operating cash flow −$839MFY25: Net borrowing −$774KFY25: Shares issued $49.6MFY25: Capital spending −$4.6MFY25: Buybacks −$1.3B$49.6MFY25FY26: Operating cash flow −$750MFY26: Shares issued $268MFY26: Capital spending −$8.2M$268MFY26
Over these 5 years operating cash flow totalled −$3.9B; the largest uses were operating cash flow ($3.9B) and buybacks ($1.3B). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$3.8B
Debtnone
Net cash$3.8B
Cash runway4.7 years

Roivant Sciences is burning cash: its operations consume cash, a free cash flow of −$821M a year at the current rate against $3.8B of cash and investments: a runway of about 4.7 years before any new financing.

Where the cash came from and went

Roivant Sciences: sources (+) and uses (−) of cash, Q1 FY27Roivant Sciences: sources (+) and uses (−) of cash, Q1 FY27Other investing$282MOperating cash flow−$271MBuybacks−$207MCash drawn (+) / kept (−)$170MShares issued$76.0MOther financing−$50.8MCapital spending−$419KExchange rates$315K
Roivant Sciences: sources (+) and uses (−) of cash, TTM to Q1 FY27Roivant Sciences: sources (+) and uses (−) of cash, TTM to Q1 FY27Operating cash flow−$816MOther investing$689MShares issued$314MOther financing−$174MCash drawn (+) / kept (−)−$11.9MCapital spending−$4.6MExchange rates$3.3M

From profit to cash

Roivant Sciences: net income to operating cash flow, Q1 FY27Roivant Sciences: net income to operating cash flow, Q1 FY27Net income−$291MDepreciation & amortization$600KStock-based pay$83.3MGains on investments−$36.6MOther non-cash$9.8MPayables$7.1MAccrued liabilities−$13.9MPrepaid and other assets−$23.8MOther liabilities$7.9MIncome taxes payable−$10.2MOperating cash flow−$271M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q1 FY27−$271M−$419K−$207M—$76.0M$170M−$271M
Q4 FY26−$164M−$1.3M——$51.2M$57.8M−$165M
Q3 FY26−$196M$4.9M——$119M−$242M−$192M
Q2 FY26−$186M−$7.8M——$68.3M$1.4M−$194M
Q1 FY26−$204M−$4.0M−$208M—$30.1M$1.5B−$208M
Q4 FY25−$173M−$811K−$295M—$12.6M−$724M−$173M
Q3 FY25−$207M−$1.8M−$243M−$112K$28.1M$27.2M−$209M
Q2 FY25−$267M−$996K−$106M−$333K$6.6M$3.7B−$268M

Roivant Sciences: income statement and cash flow

Roivant Sciences, Q1 FY27: revenue $1.4M (-34% year over year). The chart follows the revenue to costs, profit and cash.

Roivant Sciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.